Creating new proteins to target and degrade hard-to-reach disease-causing proteins
Official title: Computational design and evaluation of peptide-guided protein degraders
Funded at Ubiquitx, INC. · NIH-10830693 · Data updated 2026-11-12
This study is exploring a new way to create treatments that can target and break down stubborn proteins linked to various diseases, which could help patients who currently have limited options for their conditions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ubiquitx, INC. NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | March 1, 2024 |
| Project end | February 28, 2026 |
| Funding year | 2024 |
| Award (this year) | $306,872 |
| NIH project number | 1R41GM153081-01 |
| Project ID | NIH-10830693 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with conditions linked to proteins that are currently considered undruggable.
✕Less likely to help
Patients whose conditions are not related to the targeted proteins or who do not have diseases caused by intracellular protein dysfunction may not benefit from this research.
What this research studies
This research focuses on developing innovative mRNA therapeutics that can target and degrade proteins that are typically difficult to reach with conventional drugs. By designing specialized proteins called ubiquibodies, which combine a protein degradation mechanism with a guiding peptide, the research aims to selectively eliminate problematic proteins linked to various diseases. Patients may benefit from this approach as it could lead to new treatments for conditions caused by these 'undruggable' proteins. The methodology involves computational design and genetic engineering to create these targeted therapies.
Why it matters
Potential benefit: If successful, this research could provide new treatment options for patients with diseases caused by hard-to-target proteins.
How similar studies have gone: While the approach of using protein degraders is gaining traction, this specific method of computationally designing ubiquibodies is relatively novel and has not been extensively tested in prior research.
Where this research is happening
-
Ubiquitx, INC.
New York, United States Active
Researchers
- Principal investigator: Camargo, Luiz Miguel Quinn — Ubiquitx, INC.
- Study coordinator: Camargo, Luiz Miguel Quinn
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.